Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Multiple sclerosis: clinical presentation, diagnosis and treatment.
Copaxone
Mitoxantrone exerts both cytotoxic and immunoregulatory effects on activated microglial cells.
Reversible cerebral vasoconstriction syndrome associated with interferon beta-1a use for multiple sclerosis.
Headache in relapse and remission phases of multiple sclerosis: A case-control study.
Interferon beta-1a long-term therapy related to pulmonary arterial hypertension in multiple sclerosis patients.
Multiple sclerosis: association with HL-A3.
Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.
The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders.
Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process.
Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study.
Role of regulatory b cells in neuroimmunologic disorders.
Radiologically isolated syndrome: 5-year risk for an initial clinical event.
DNA strand breakage by peroxidase-activated mitoxantrone.
Multiple Sclerosis Patient-Specific Primary Neurons Differentiated from Urinary Renal Epithelial Cells via Induced Pluripotent Stem Cells.
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
Multiple Sclerosis.
Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound.
Natalizumab may reduce cognitive changes and brain atrophy rate in relapsing-remitting multiple sclerosis: a prospective, non-randomized pilot study.
Protective effects of monomethyl fumarate at the inflamed blood-brain barrier.
Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity.
Long-term effectiveness of glatiramer acetate in clinical practice conditions.

Pages